US2015376251A1PendingUtilityA1

Method for Inducing Formation of Neurons from Embryonal Stem Cells

41
Individually held — no corporate assignee on recordPriority: Nov 1, 2001Filed: Mar 2, 2015Published: Dec 31, 2015
Est. expiryNov 1, 2021(expired)· nominal 20-yr term from priority
Inventors:Robert H. BroylesRobert A. FloydAustin C. RothVisar Belegu
A61K 2035/124A61K 48/00C07K 14/47A61K 38/1709A61K 35/30C12N 2501/385C12N 5/0694
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method is described for inducing formation of neurons from embryonal stem cells, by utilizing an exogenous ferritin-H inducer.

Claims

exact text as granted — not AI-modified
1 . A method for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell, the method comprising the steps of:
 providing at least one human β-globin producing cell; 
 providing a ferritin-H protein; and 
 contacting the at least one human β-globin producing cell with the ferritin-H protein, whereby the ferritin-H protein is introduced into the at least one human β-globin producing cell, wherein the ferritin-H protein represses production of β-globin protein and increases production of γ-globin protein in the human β-globin producing cell. 
 
     
     
         2 . The method of  claim 1 , wherein the ferritin-H protein is human ferritin-H protein. 
     
     
         3 . The method of  claim 1 , wherein the ferritin-H protein is a functional derivative of human ferritin-H protein. 
     
     
         4 . The method of  claim 1 , wherein the step of contacting the at least one human β-globin producing cell with the ferritin-H protein occurs in vitro. 
     
     
         5 . The method of  claim 1 , wherein a polypeptide transfection agent is administered together with the ferritin-H protein. 
     
     
         6 . A method for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell, the method comprising the steps of:
 providing at least one human β-globin producing cell; and 
 introducing a nucleic acid segment encoding a ferritin-H protein into the at least one human β-globin producing cell, whereby the cell produces ferritin-H protein and the ferritin-H protein so produced represses production of β-globin protein and increases production of γ-globin protein in the human β-globin producing cell. 
 
     
     
         7 . The method of  claim 6 , wherein the ferritin-H protein is human ferritin-H protein. 
     
     
         8 . The method of  claim 6 , wherein the ferritin-H protein is a functional derivative of human ferritin-H protein. 
     
     
         9 . The method of  claim 6 , wherein the step of introducing a nucleic acid segment encoding a ferritin-H protein into the at least one human β-globin producing cell occurs in vitro. 
     
     
         10 . The method of  claim 6 , wherein a polynucleotide transfection reagent is administered together with the nucleic acid segment encoding the ferritin-H protein. 
     
     
         11 . The method of  claim 6 , the step of introducing a nucleic acid segment encoding a ferritin-H protein is further defined as introducing a plasmid vector comprising a nucleic acid segment encoding a ferritin-H protein. 
     
     
         12 . The method of  claim 6 , the step of introducing a nucleic acid segment encoding a ferritin-H protein is further defined as introducing a viral vector comprising a nucleic acid segment encoding a ferritin-H protein. 
     
     
         13 . A method for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell, the method comprising the steps of:
 providing at least one human β-globin producing cell; 
 providing an exogenous ferritin-H inducer; and 
 contacting the at least one human β-globin producing cell with the exogenous ferritin-H inducer, whereby the exogenous ferritin-H inducer elevates production of ferritin-H in the at least one human β-globin producing cell, wherein the ferritin-H represses production of β-globin protein and increases production of γ-globin protein in the human β-globin producing cell. 
 
     
     
         14 . The method of  claim 13 , wherein the step of contacting the at least one human β-globin producing cell with the exogenous ferritin-H inducer occurs in vitro. 
     
     
         15 . The method of  claim 13 , wherein the exogenous ferritin-H inducer is retinoic acid. 
     
     
         16 . The method of  claim 13 , wherein the exogenous ferritin-H inducer is abscissic acid. 
     
     
         17 . A method for treating sickle cell disease, the method comprising the steps of:
 obtaining blood from a sickle cell patient;   culturing cells in the blood to produce erythroid precursor cells wherein the hemoglobin phenotype of the erythroid precursor cells is HbS;   providing a ferritin-H protein;   contacting the erythroid precursor cells with the ferritin-H protein, whereby the ferritin-H protein is introduced into the erythroid precursor cells;   culturing the erythroid precursor cells for a length of time sufficient to change hemoglobin phenotype of at least a portion of the erythroid precursor cells from HbS to HbF; and   reinfusing the erythroid precursor cells back to the sickle cell patient.   
     
     
         18 . The method of  claim 17 , wherein the ferritin-H protein is human ferritin-H protein. 
     
     
         19 . The method of  claim 17 , wherein the ferritin-H protein is a functional derivative of human ferritin-H protein. 
     
     
         20 . The method of  claim 17 , wherein a protein transfection agent is administered together with the ferritin-H protein. 
     
     
         21 . A method for treating sickle cell disease, the method comprising the steps of:
 obtaining blood from a sickle cell patient;   culturing cells in the blood to produce erythroid precursor cells wherein the hemoglobin phenotype of the erythroid precursor cells is HbS;   introducing a nucleic acid segment encoding a ferritin-H protein into the erythroid precursor cells, whereby ferritin-H protein is produced in the erythroid precursor cells;   culturing the erythroid precursor cells for a length of time sufficient to change hemoglobin phenotype of at least a portion of the erythroid precursor cells from HbS to HbF; and   reinfusing the erythroid precursor cells back to the sickle cell patient.   
     
     
         22 . The method of  claim 21 , wherein the ferritin-H protein is human ferritin-H protein. 
     
     
         23 . The method of  claim 21 , wherein the ferritin-H protein is a functional derivative of human ferritin-H protein. 
     
     
         24 . The method of  claim 21 , wherein a polynucleotide transfection reagent is administered together with the nucleic acid segment encoding the ferritin-H protein. 
     
     
         25 . The method of  claim 21 , the step of introducing a nucleic acid segment encoding a ferritin-H protein is further defined as introducing a plasmid vector comprising a nucleic acid segment encoding a ferritin-H protein. 
     
     
         26 . The method of  claim 21 , the step of introducing a nucleic acid segment encoding a ferritin-H protein is further defined as introducing a viral vector comprising a nucleic acid segment encoding a ferritin-H protein. 
     
     
         27 . A method for treating sickle cell disease, the method comprising the steps of:
 obtaining blood from a sickle cell patient;   culturing cells in the blood to produce erythroid precursor cells wherein the hemoglobin phenotype of the erythroid precursor cells is HbS;   providing an exogenous ferritin-H inducer;   contacting the erythroid precursor cells with the exogenous ferritin-H inducer, whereby the exogenous ferritin-H inducer elevates production of ferritin-H in the erythroid precursor cells;   culturing the erythroid precursor cells for a length of time sufficient to change hemoglobin phenotype of at least a portion of the erythroid precursor cells from HbS to HbF; and   reinfusing the erythroid precursor cells back to the sickle cell patient.   
     
     
         28 . The method of  claim 27 , wherein the exogenous ferritin-H inducer is retinoic acid. 
     
     
         29 . The method of  claim 27 , wherein the exogenous ferritin-H inducer is abscissic acid. 
     
     
         30 . A method for inducing formation of neurons in cultured embryonal carcinoma stem cells, the method comprising the steps of:
 providing cultured embryonal carcinoma stem cells; and   contacting the cultured embryonal carcinoma stem cells with an exogenous ferritin-H inducer.   
     
     
         31 . The method of  claim 30 , wherein the exogenous ferritin-H inducer is retinoic acid. 
     
     
         32 . The method of  claim 30 , wherein the exogenous ferritin-H inducer is abscissic acid.

Join the waitlist — get patent alerts

Track US2015376251A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.